Free tool
FAERS Monitor: Vemlidy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208464 or its brand name (Vemlidy, Tenofovir Alafenamide Fumarate). Reports on generic versions are filed under their own applications.
Reports
4,168
Serious
2,952
71% of reports
Hospitalization
1,184
Death reported
436
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death254
- product dose omission issue184
- off label use172
- fatigue144
- drug ineffective125
- diarrhoea96
- headache92
- nausea92
- drug interaction89
- product use issue88
- neoplasm malignant72
- rash72
- hepatitis b71
- product dose omission71
- intentional dose omission69
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 108 |
| 2018 | 310 |
| 2019 | 513 |
| 2020 | 413 |
| 2021 | 536 |
| 2022 | 551 |
| 2023 | 510 |
| 2024 | 473 |
| 2025 | 419 |
| 2026 | 331 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,991 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis bSignal | 71 | 60.2 | 47.7 | 4,024 |
| intentional dose omissionSignal | 69 | 12.2 | 9.7 | 700 |
| product dose omissionSignal | 71 | 5.5 | 4.4 | 257 |
| neoplasm malignantSignal | 72 | 5.4 | 4.3 | 258 |
| product dose omission issueSignal | 184 | 3.2 | 2.7 | 273 |
| drug interactionSignal | 89 | 2.8 | 2.3 | 104 |
| product use issueSignal | 88 | 2.4 | 1.9 | 68 |
| death | 254 | 1.5 | 1.3 | 42 |
| off label use | 172 | 1.0 | 0.9 | 0 |
| fatigue | 144 | 0.9 | 0.8 | 1 |
| rash | 72 | 0.8 | 0.7 | 2 |
| diarrhoea | 96 | 0.8 | 0.6 | 8 |
| headache | 92 | 0.7 | 0.6 | 8 |
| nausea | 92 | 0.6 | 0.5 | 27 |
| drug ineffective | 125 | 0.5 | 0.4 | 75 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.